How long does it take for nattokinase to start working?

Nattokinase begins changing your blood chemistry roughly two hours after you swallow the capsule — and you will not feel a thing.

In a double-blind crossover trial, a single 2,000 FU dose measurably altered clotting markers at the 2-hour blood draw [1]. The outcomes people actually care about run on a far slower clock: the randomised blood pressure trials ran for 8 weeks [3]. Here is what happens on each timescale.

Table of Contents

1. The Short Answer: Three Different Clocks
2. What Happens in the First 24 Hours
3. Why 8 Weeks Is the Number That Matters
4. Beyond 8 Weeks: What Longer Use Changes
5. Five Things That Shift Your Personal Timeline
6. Knowing What Your 8-Week Test Is Testing
7. Frequently Asked Questions
8. Conclusion
9. Research References

1. The Short Answer: Three Different Clocks

Nattokinase research runs on three separate timescales, and mixing them up is the most common reason people conclude the supplement has failed after ten days. Each clock answers a different version of the question.

• Hours: fibrinolytic and clotting markers shift between 2 and 8 hours after a single 2,000 FU dose, then drift back toward baseline [1].
• Weeks: blood pressure changes emerged over 8 weeks in the randomised trials [3].
• Months: coagulation factors declined steadily across 2 months of daily use at 4,000 FU [6], and arterial imaging endpoints required 12 months at much higher doses.

So the enzyme "starts working" almost immediately in the narrow biochemical sense. What it does not do is produce a change you can perceive on day one, day ten, or ever. A 12-month study of 1,062 participants averaging 67.5 years old reported reduced carotid plaque and improved lipids at 10,800 FU per day, while 3,600 FU per day produced nothing [8] — that study was retrospective and uncontrolled, so it carries less weight than the randomised evidence, but it illustrates how far out the slowest endpoints sit.

2. What Happens in the First 24 Hours

The most direct answer comes from a pilot pharmacokinetic study in which 11 healthy participants aged 21 to 65 took a single 100 mg capsule delivering 2,000 FU. Serum levels rose detectably from the 2-hour mark, and peaked at 13.3 ± 2.5 hours before remaining elevated through the 24-hour draw [2]. That is a slow, flat curve rather than a spike — closer to a background shift than a dose you feel arriving.

One honest caveat: that study used an antibody assay that responds to both nattokinase and its breakdown products, so it confirms the enzyme is absorbed and circulating without proving how much remains biologically active. The functional evidence comes from a separate crossover trial in 12 healthy men, where blood was drawn at 2, 4, 6 and 8 hours. D-dimer rose at 6 and 8 hours, fibrin degradation products rose at 4 hours, factor VIII activity fell at 4 and 6 hours, and clotting time lengthened at 2 and 4 hours [1].

Every one of those changes stayed inside the normal laboratory reference range, and no participant reported a side effect. That is the whole story of day one: something real is happening, entirely below the threshold of sensation. If you want the biochemistry in detail, our guide to how nattokinase works covers the fibrinolytic pathway, and our companion article on how to tell whether nattokinase is working covers what you can and cannot measure at home.

3. Why 8 Weeks Is the Number That Matters

If you are asking how long before nattokinase does something you could actually detect, the research answer is eight weeks. The first randomised trial enrolled 86 adults with untreated systolic pressure between 130 and 159 mmHg and gave them 2,000 FU daily or placebo. Among the 73 who completed it, the nattokinase group finished 5.55 mmHg lower in systolic and 2.84 mmHg lower in diastolic pressure [3] than controls.

A North American multicentre trial in 79 hypertensive adults used the same 8-week window with 100 mg of K2-removed nattokinase daily, and reported diastolic pressure of 84 mmHg in the nattokinase group versus 87 mmHg on placebo, alongside a 15% reduction in von Willebrand factor that reached only a statistical trend [4]. A 2023 meta-analysis covering six randomised trials and 546 participants pooled the three of them that measured blood pressure — 223 people in total — and put the average effect at 3.45 mmHg systolic and 2.32 mmHg diastolic [5], with four of those six trials taking their reading at week 8.

Those are real but modest numbers, which is exactly why the timeline matters so much. A 3 to 5 mmHg shift is invisible without disciplined measurement over a defined window, and it is not something that arrives on a particular morning — it accumulates. Judging nattokinase at three weeks is not an early verdict; it is no verdict at all. Our review of what the blood pressure research actually shows breaks the trials down individually.

4. Beyond 8 Weeks: What Longer Use Changes

Some markers keep moving after the two-month mark. An open-label trial in 45 participants — healthy volunteers, people with cardiovascular risk factors, and dialysis patients — measured coagulation factors on days 3, 7, 28 and 56 while taking two 2,000 FU capsules daily — 4,000 FU, twice the dose used in the blood pressure trials. Levels declined continuously across the whole period rather than settling early, ending at 9% lower fibrinogen, 14% lower factor VII and 17% lower factor VIII in the healthy group [6], with similar reductions in the other two groups and no significant adverse events. The dose caveat matters: this is the clearest evidence that coagulation markers keep moving past week 8, but it was produced at twice the standard intake.

The counterweight is the largest and longest trial ever run on this enzyme. Researchers randomised 265 adults of median age 65.3 with no clinical cardiovascular disease to 2,000 FU daily or placebo and followed them for a median of three years. They found no difference in carotid thickness, arterial stiffness, blood pressure or any laboratory measure [7] — and no detectable coagulation changes at the 1-week, 1-month, 3-month or 6-month checkpoints either.

Read together, these results are less contradictory than they look. Waiting longer does not manufacture an effect where the starting conditions offer nothing to change. If your blood pressure and clotting factors are already comfortably normal, three years will show you what eight weeks showed you.

5. Five Things That Shift Your Personal Timeline

Two people taking identical capsules can reach measurable results on very different schedules. These five variables explain most of the gap.

• Your baseline. The trials that found effects recruited people with elevated readings — systolic pressure of 130 to 159 mmHg in the 2008 study [3]. The 3-year trial that found nothing recruited low-risk adults [7].
• Your dose. Blood pressure endpoints responded at 2,000 FU daily; the arterial imaging endpoints needed 10,800 FU daily for 12 months [8].
• Delivery and timing. Nattokinase is a protein, and a capsule releasing in the stomach exposes it to acid before absorption — which is why the standard protocol across the research is one capsule daily on an empty stomach.
• Consistency. Serum levels from a single dose peak at roughly 13 hours [2], so daily dosing is what maintains the exposure the trials measured. Missed days reset the clock.
• Medications. Anyone taking warfarin, apixaban, rivaroxaban, aspirin or clopidogrel needs physician oversight before starting.

That last point has its own timeline, and it is a short one. A published case report describes acute cerebellar haemorrhage in a 52-year-old woman with prior ischaemic stroke after just 7 days of nattokinase at 400 mg daily alongside aspirin [9]. Benefits accumulate over weeks; bleeding risk does not wait that long. Our guides to dosage and timing and the full side effect profile cover both in depth.

6. Knowing What Your 8-Week Test Is Testing

An eight-week trial of your own is only as meaningful as the capsule you run it with. Fibrinolytic units measure enzyme activity, not weight — a label can state 2,000 FU while the enzyme inside has degraded in transit, and nothing about the experience would tell you.

BioAbsorb Nattokinase Enzyme delivers 100 mg providing 2,000 FU per capsule — the same dose used in the 2008 blood pressure trial and the 3-year prevention study — taken as one capsule daily on an empty stomach. Every batch is third-party tested to confirm at least 2,000 FU of activity, alongside screening for heavy metals, gluten and microbial contaminants.

Three formulation details matter specifically for timeline questions. The capsule uses DRcaps delayed-release technology, protecting the enzyme from stomach acid without the phthalates and plasticizers found in conventionally enteric-coated capsules. The formula is free of vitamin K2, which is relevant because the North American trial that recorded diastolic reductions used K2-removed nattokinase, and because K2 complicates matters for anyone already supplementing it. And it is non-GMO, 100% vegetarian and free of gluten, nuts, eggs, dairy, fish and shellfish, manufactured in a Canadian GMP-certified facility.

At $49.87 for 180 capsules — roughly $0.28 per day — a full 8-week evaluation costs about 56 capsules, or under $16 of a six-month supply.

Frequently Asked Questions

How long until I feel nattokinase working?

You should not expect to feel anything at all. Fibrin breakdown in circulating blood has no sensory feedback attached to it, and in the single-dose crossover trial, every measurable change stayed within the normal reference range with no reported side effects [1]. Absence of sensation is the expected result, not a sign the capsule failed.

Does taking it on an empty stomach make it work faster?

An empty stomach is the standard protocol across the research literature, because nattokinase is a protein and food slows and complicates its passage to the small intestine. It is better understood as protecting how much enzyme survives than as accelerating onset. If you have been taking it with meals and seen nothing at week 8, correcting the timing before drawing conclusions is reasonable.

How long should I take it before deciding it is not working?

Eight weeks, because that is the window used in the randomised trials and in four of the six trials pooled in the 2023 meta-analysis [5]. Run a 7-day home blood pressure baseline before your first capsule and an identical block at week 8, then compare the averages rather than individual readings.

Does one capsule keep working all day?

Serum concentrations from a single 100 mg dose peak around 13.3 hours and remain detectable at 24 hours [2], which is consistent with the once-daily protocol used in the trials. The functional markers measured in the crossover study had largely drifted back toward baseline by the 8-hour draw, so daily consistency matters more than time of day.

Will a higher dose produce results sooner?

Not for blood pressure, where 2,000 FU daily is the studied dose. Higher intakes were used for arterial imaging endpoints, where 10,800 FU daily for 12 months produced changes and 3,600 FU daily did not [8]. Escalating the dose on your own raises bleeding risk without a corresponding evidence base, and should involve your physician.

How quickly could side effects appear?

Faster than benefits. Nattokinase was well tolerated across the trials, and toxicology review found 10 mg/kg per day for 4 weeks was well tolerated in healthy human volunteers [10]. But the published haemorrhage case followed just 7 days of high-dose use alongside aspirin [9], so any new bruising or prolonged bleeding is a reason to stop and call a healthcare provider.

Conclusion

Nattokinase starts acting on blood chemistry within about 2 hours, peaks in serum near 13 hours, and produces its first measurable clinical effect — in the pooled trial data, an average 3.45 mmHg systolic reduction [5] — over roughly 8 weeks of daily use. Give it that full window, measure properly at both ends, and speak with your physician first if you take any anticoagulant. If you want a capsule whose activity is verified rather than assumed, BioAbsorb Nattokinase Enzyme is third-party tested for 2,000 FU per capsule.

Research References

1. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, Vol. 5 (2015). Double-blind placebo-controlled crossover trial in 12 healthy men; a single 2,000 FU dose raised D-dimer at 6 and 8 hours, raised fibrin degradation products at 4 hours, reduced factor VIII activity at 4 and 6 hours, and prolonged activated partial thromboplastin time at 2 and 4 hours, with all changes remaining inside the normal reference range.
2. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Alternative Therapies in Health and Medicine, Vol. 19, Issue 3 (2013). Eleven healthy participants took a single 100 mg (2,000 FU) dose; serum concentrations rose detectably from 2 hours, peaked at 13.3 ± 2.5 hours and remained elevated at 24 hours. The antibody assay used detects both nattokinase and its metabolites, so biological activity of the detected enzyme was not confirmed.
3. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research, Vol. 31, Issue 8 (2008). 86 adults with untreated systolic pressure of 130–159 mmHg received 2,000 FU daily or placebo for 8 weeks; net reductions among the 73 completers were 5.55 mmHg systolic and 2.84 mmHg diastolic.
4. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integrated Blood Pressure Control, Vol. 9 (2016). 79 hypertensive adults took 100 mg of K2-removed nattokinase or placebo for 8 weeks; diastolic pressure was 84 mmHg in the nattokinase group versus 87 mmHg on placebo, with von Willebrand factor reduced by 15% in the nattokinase group — a difference that reached only a statistical trend (p<0.09), not significance. The study was sponsored by the distributor of the product tested.
5. Nattokinase supplementation and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Reviews in Cardiovascular Medicine, Vol. 24, Issue 8 (2023). Included 6 randomised trials and 546 participants overall; the blood pressure analysis pooled 3 of those trials (223 participants), finding average reductions of 3.45 mmHg systolic and 2.32 mmHg diastolic versus placebo. Four of the six pooled trials assessed outcomes at week 8, and 8 weeks was the most common follow-up window across the seven trials the review included in total.
6. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutrition Research, Vol. 29, Issue 3 (2009). Open-label self-controlled trial in 45 participants across healthy, cardiovascular-risk and dialysis groups taking two 2,000 FU capsules daily (4,000 FU total) for 2 months, with measurements at days 3, 7, 28 and 56; coagulation factors declined continuously, ending 9%, 14% and 17% lower for fibrinogen, factor VII and factor VIII in the healthy group.
7. Nattokinase atherothrombotic prevention study: a randomized controlled trial. Clinical Hemorheology and Microcirculation, Vol. 78, Issue 4 (2021). 265 adults of median age 65.3 without clinical cardiovascular disease took 2,000 FU or placebo for a median of three years, with no significant difference in carotid intima-media thickness, arterial stiffness, blood pressure or any laboratory measure, and no detectable coagulation changes at 1 week or 1, 3 and 6 months.
8. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: a clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, Vol. 9 (2022). Retrospective, non-randomised study without placebo control (a corrigendum was published in December 2022); participants averaging 67.5 years showed reduced carotid plaque, intima-media thickness and lipids after 12 months at 10,800 FU per day, while 3,600 FU per day was ineffective.
9. Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. Internal Medicine, Vol. 47, Issue 5 (2008). Case report of acute cerebellar haemorrhage in a 52-year-old woman with prior ischaemic stroke after 7 days of nattokinase at 400 mg daily alongside aspirin. Causality cannot be established given her clinical history.
10. Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food and Chemical Toxicology, Vol. 88 (2016). Reports that 10 mg/kg per day for 4 weeks was well tolerated in healthy human volunteers, alongside subchronic animal toxicity data supporting a low toxicological concern for oral nattokinase.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.